Biblio
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9(4):e301-e311.
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leuk Res. 2018;74:86-88.
Incidence of blast phase in myelofibrosis according to anemia severity. EJHaem. 2023;4(3):679-689.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer. 2023.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2019.
RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA. Hematol Oncol. 2020.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Cancer. 2023.
Second cancers in MPN: survival analysis from an international study. Am J Hematol. 2019.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020.
Treating early-stage myelofibrosis. Ann Hematol. 2018.
. Treatment Recommendations for Chronic Myeloid Leukemia. Mediterr J Hematol Infect Dis. 2014;6(1):e2014005.
. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematol. 2021;8(9):e658-e665.